PACS Group (PACS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Revenue for Q2 2026 reached $1.43 billion, up 9.1% year-over-year, with net income rising 49.8% to $76.3 million and adjusted EBITDA up 25% to $166.8 million, driven by occupancy and patient mix improvements.
Closed on 20 Texas facilities from Eduro Healthcare, with 14 more expected to close in Q3/Q4 2026, expanding presence to 21 states and increasing SNF beds to 36,423.
Operates 324–344 facilities across 17 states, serving over 31,900 patients daily with approximately 48,000 employees.
Quality outcomes improved, with 83.6% of skilled nursing facilities rated four or five stars by CMS and mature facilities averaging 4.5 stars and 93.8% occupancy.
Growth driven by acquiring underperforming facilities and converting them to higher-acuity, value-add transitional care.
Financial highlights
Q2 2026 revenue: $1.43 billion, up 9.1% year-over-year; net income: $76.3 million, up 49.8%; adjusted EBITDA: $166.8 million, up 25%; adjusted EPS: $0.63.
Cash from operations for first six months: $371.8 million; available liquidity: $756.6 million as of June 30, 2026.
Adjusted EBITDAR: $261.5 million; margin expanded to 11.7%.
Operating income for Q2 2026 was $109.3 million, up 35.8% year-over-year.
Six-month revenue was $2.85 billion, up 10.1% year-over-year; six-month net income was $157.1 million, up 97.9%.
Outlook and guidance
Raised full-year 2026 revenue guidance to $5.75–$5.85 billion, representing 10% growth over 2025.
Increased adjusted EBITDA guidance to $640–$660 million, up 29% over 2025.
Guidance includes only closed acquisitions and partial-year contribution from 20 Texas facilities; excludes pending deals and supplemental payments.
Management expects current cash balances and cash flow from operations to cover operating needs for at least the next 12 months.
Expect continued strong performance and additional acquisitions before year-end.
Latest events from PACS Group
- Board elections, auditor ratification, and executive pay all approved without stockholder questions.PACS
AGM 2026 - Q1 2026 revenue up 11.2%, net income up 184%, and EBITDA guidance raised to $605–$625M.PACS
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.PACS
Proxy filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PACS
Proxy filing - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 2025 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference - Offering 2.78M shares at $39.67 to repay debt; founders retain control; strong growth, high regulatory risk.PACS
Registration Filing - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 2024